Enbrel® (etanercept)

Policy Number: 5.01.501  Last Review: 9/2014

Policy
BCBSKC will provide coverage for Enbrel® (etanercept) when it is determined to be medically necessary because the criteria shown below are met.

When Policy Topic is covered
Enbrel® (etanercept) requires prior authorization through the pharmacy services area. Enbrel® is considered medically necessary in the treatment of the following conditions:

Rheumatoid arthritis
- In combination with methotrexate or alone for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis*, in patients who have had inadequate response to one or more DMARDs (disease-modifying anti-rheumatic drugs (i.e., methotrexate, sulfasalazine).
- Etanercept will be considered for coverage at a dosage of 25 mg injected subcutaneously twice weekly 72-96 hours apart or 50 mg injected subcutaneously once weekly as specified in the product information provided by the manufacturer.

Polyarticular juvenile idiopathic arthritis
- Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients ages 2 and older.

Psoriatic arthritis
- Reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis. Etanercept can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone.
- Etanercept will be considered for coverage at a dosage of 25 mg injected subcutaneously twice weekly 72-96 hours apart or 50 mg injected subcutaneously once weekly as specified in the product information provided by the manufacturer.

Ankylosing spondylitis
- Reducing signs and symptoms in patients with active ankylosing spondylitis*; in patients who have not had an adequate response to conventional therapy; (i.e., nonsteroidal anti-inflammatory drugs (NSAIDs), sulfasalazine, methotrexate);
- Etanercept will be considered for coverage at a dosage of 25 mg injected subcutaneously twice weekly 72-96 hours apart or 50 mg injected subcutaneously once weekly as specified in the product information provided by the manufacturer.
**Plaque Psoriasis**

- for the treatment of adult patients with chronic moderate to severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when topical therapies, other systemic therapies (i.e., methotrexate), and phototherapy are medically less appropriate;
- The recommended dose of etanercept for the treatment of psoriasis is 50mg injected subcutaneously twice weekly (administered 3-4 days apart) for 3 months followed by a reduction to a maintenance dose of 50mg per week.

**When Policy Topic is Not Covered**

Enbrel® (etanercept) is considered investigational when used for all other conditions, including, but not limited to:

- The combined use of etanercept and a monoclonal antibody, tumor necrosis factor (TNF) or interleukin-1 (IL-1) inhibitor, such as adalimumab, infliximab or anakinra,
- Asthma
- Cancer anorexia/weight loss syndrome
- Cardiac transplant recipients
- Chronic discogenic low back pain
- Epidural administration
- Graft-Versus-Host disease
- Hepatitis C Infection
- Metabolic Syndrome
- Non-plaque Psoriasis
- Polymyalgia Rheumatica
- Polymyositis
- Reactive Arthritis
- Sarcoidosis
- Sjogren’s Syndrome
- Type 1 diabetes
- Type 2 diabetes
- Wegener’s Granulomatosis

**Description of Procedure or Service**

Enbrel® (etanercept) is a dimeric fusion protein administered subcutaneously that binds to and inhibits tumor necrosis factor alpha and beta, a cytokine that plays an important role in a variety of inflammatory processes. It is approved by the FDA to treat rheumatoid arthritis, polyarticular-course juvenile rheumatoid arthritis, psoriatic arthritis, psoriasis and ankylosing spondylitis.

**Considerations**

Based on a study of 50 mg etanercept twice weekly in patients with RA that suggested higher incidence of adverse reactions but similar ACR response rates, doses higher than 50 mg per week are not recommended.

Although Enbrel® has been assigned a HCPCS infusion code, benefits will pay through pharmacy.

This Blue Cross and Blue Shield of Kansas City policy statement was developed using available resources such as, but not limited to: Hayes Medical Technology Directory, Food and Drug Administration (FDA) approvals, Facts and Comparisons, National specialty guidelines, Local medical policies of other health plans, Medicare (CMS), Local providers.
Rationale
There are many treatments for rheumatic disorders that are effective, have known long-term safety profiles, and are recommended by national treatment guidelines. Non-medical therapies, such as prescribed exercise therapy, physical therapy and weight loss, are important components in any treatment plan for patients suffering from a rheumatic disorder. When a systemic medication is needed to manage one of the rheumatic disorders, oral therapies are usually the best value.

- Medications to control inflammation, such as nonsteroidal anti-inflammatory medications (e.g., meloxicam, nabumetone, and naproxen) and glucocorticoids (oral and injected into the joint) are effective for the management of symptoms, particularly during the early stages of disease.
- Orally administered disease-modifying antirheumatic drugs (DMARDs), including methotrexate (MTX), hydroxychloroquine, leflunomide, and sulfasalazine, are effective for decreasing symptoms and slowing disease progression, have a proven track record, and have been the standard of care for many years.
- Oral therapies have known potential risks. The management of these risks is well established.

Methotrexate is considered effective in the treatment of RA and the standard reference DMARD to which newer DMARDs (etanercept, anakinra, adalimumab, and leflunomide) are compared for efficacy. When non-medical therapies and oral medications are inadequate, the biologic medications (e.g. adalimumab, etanercept, infliximab, certolizumab, golimumab, or abatacept) may be appropriate. No studies have shown that any of the biologic medications are more effective than another in the treatment of rheumatic disorders, with the exception that there is indirect evidence that anakinra may be less effective than other alternatives.

- The biologic DMARDs can decrease symptoms, help preserve joint functioning, and slow the progression of rheumatic disease.
- There have been no reliable, direct-comparative trials that have demonstrated a difference in clinical effect or safety of one agent over another.
- Individual responses and tolerability are unpredictable and may vary between patients.
- Because responses vary, if one of the biologic DMARDs provides an inadequate response, another biologic medication may yet be effective.
- In rheumatoid arthritis, the best response is seen when methotrexate is used concomitantly with any of the biologics. Infliximab and golimumab have been shown to be effective only when used with methotrexate. Treatment options other than infliximab or golimumab should be considered for patients who cannot take methotrexate.

Efficacy of biologic agents in rheumatic conditions

The benefit of medications can be indirectly compared by calculating the number needed to treat (NNT). The number needed to treat is a measure of the changes of a patient achieving a benefit (how many patients need to be treated before a benefit is achieved over a certain period of time). The lower the number needed to treat, the more likely the medication will have benefit.
Table 1 summarizes the chances that certain biologic rheumatologic medications will improve joint pain and stiffness in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis:

<table>
<thead>
<tr>
<th>Biologic Medications (when used with methotrexate)</th>
<th>Rheumatoid Arthritis</th>
<th>Psoriatic Arthritis</th>
<th>Ankylosing Spondylitis</th>
</tr>
</thead>
<tbody>
<tr>
<td>adalimumab (Humira) etanercept (Enbrel) infliximab (Remicade) certolizumab (Cimzia)</td>
<td>About 1 in 3 likely to benefit (^{b}) NNT = 3 (Range 2-4)</td>
<td>About 1 in 3 likely to benefit (^{a}) NNT = 3</td>
<td>About 1 in 4 likely to benefit (^{a}) NNT = 4 (Range 3-4)</td>
</tr>
<tr>
<td>golimumab (Simponi)</td>
<td>About 1 in 5 likely to benefit NNT = 5</td>
<td>About 1 in 3 likely to benefit NNT = 3</td>
<td>About 1 in 3 likely to benefit NNT = 3</td>
</tr>
<tr>
<td>abatacept (Orencia)</td>
<td>About 1 in 4 likely to benefit (^{a}) NNT = 4 (Range 3-4)</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>anakinra (Kineret)</td>
<td>About 1 in 7 likely to benefit (^{a}) NNT = 7</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

\(^{a}\) Benefit = at least 20% improvement in joint pain and stiffness after six months of treatment.

There is reliable evidence that etanercept, adalimumab, and abatacept (when given with methotrexate) are effective in the management of patients with juvenile idiopathic arthritis (JIA). The design of the clinical studies prevents calculation of NNT for this use. [1, 41, 43]
**Efficacy of etanercept in rheumatic conditions**

Long-term experience with etanercept has been published. Persistence with therapy was reported to range between 66% at 3 years and 41% at 6 years. ACR20 scores ranged from 78% at 3 years to 73% at 6 years. [16,17] Combining etanercept with another DMARD (MTX) resulted in statistically better patient responses as measured by ACR or DAS scores than with any agent alone.[18,19] Therapy with etanercept either alone or combined resulted in improved patient responses over sulfasalazine alone in patients who had had an inadequate response to sulfasalazine.[30] The recommended dose of etanercept for adult patients with RA, PsA, or AS is 50mg weekly, given as a single subcutaneous (SC) injection or as 25mg given twice weekly SC 72-96 hours apart.[1,32] The recommended dose for pediatric patients ages 4 to 17 with active polyarticular-course JRA is 0.8mg/kg SC each week (up to a maximum of 50mg per week). In a head-to-head trial comparing etanercept 25mg twice weekly to 50mg twice weekly in patients with active rheumatoid arthritis, the higher dose resulted in similar efficacy responses, but had an increase in upper respiratory tract infections (26% vs. 4%, P=0.027, NNH = 6) [21]

**Efficacy of biologic agents in plaque psoriasis [1, 39, 43-46, 50]**

Table 2 summarizes the chances that certain biologic medications will improve size and thickness of skin lesions, redness, and itching in moderate to severe plaque psoriasis:

<table>
<thead>
<tr>
<th>Medications</th>
<th>Benefit In Moderate to Severe Plaque Psoriasis</th>
</tr>
</thead>
<tbody>
<tr>
<td>etanercept (Enbrel), adalimumab (Humira), infliximab (Remicade), ustekinumab (Stelara)</td>
<td>About 1 in 3 likely to benefit a NNT = 3 (Range 2-4)</td>
</tr>
<tr>
<td>alefacept (Amevive)</td>
<td>About 1 in 9 likely to benefit a NNT = 9 (Range 7-10)</td>
</tr>
</tbody>
</table>

*a Benefit = at least 75% improvement in size and thickness of skin lesions, redness, and itching after 12 to 16 weeks of treatment.

**Efficacy of etanercept in plaque psoriasis**

Etanercept was shown to be safe and efficacious in two double-blind, randomized controlled trials. There are no data available establishing that continued therapy with etanercept at a dose of 50 mg twice weekly (beyond 3 months of initial therapy) offers a significant advantage over continued therapy with 50 mg of etanercept weekly. [29] In one 24-week double-blind study, 672 patients with plaque psoriasis were randomized to received etanercept 25 mg once weekly (low dose), 25 mg twice weekly (medium dose) or 50 mg twice weekly (high dose) for 24 weeks. [12] High-dose etanercept appeared to be more effective initially, but the incremental benefit was not sustained.

- At the initial, 12-week efficacy assessment, there was a statistically significant difference in the proportion of patients achieving a PASI 75 response when patients receiving an initial dose of 25 mg twice weekly were compared to patients receiving an initial dose of 50 mg twice weekly (34% versus 49%, respectively; p<0.005).[12]
- At 24 weeks, there was at least a 75% improvement in the psoriasis area and severity index (PASI 75 response) in 25% of patients in the low-dose group, 44% of patients in the medium dose-group, and 59% of the patients in the high-dose group, compared with 4% in the placebo group. [12] There was no statistical difference between groups receiving 25 mg twice weekly and 50 mg twice weekly at 24 weeks.

Another blinded, randomized, controlled trial evaluated 618 patients with moderate-to-severe plaque psoriasis who were randomized to 12 weeks of placebo or etanercept 50 mg twice weekly. [23] At week 12, 47% of the patients receiving etanercept achieved a PASI 75 score, as compared to 5% of the patients receiving placebo (P<0.0001). After week 12, patients were allowed to continue etanercept...
50 mg SC twice weekly, or begin etanercept 50 mg SC twice weekly (placebo patients) in an open-label extension trial for up to 96 weeks. No significant safety signals were detected (see the Safety section). PASI 75 scores at 96 weeks were approximately 51% in both groups, which is consistent with other studies of etanercept in plaque psoriasis. [29] Patients with plaque psoriasis (n=409) who responded to etanercept after a 24-week blinded, randomized controlled trial were re-randomized to receive their previous dose (25 mg or 50 mg twice weekly) or placebo for a single 12-week retreatment after disease relapse. Response rates seen after re-treatment were similar to those seen during the original treatment. There was no significant difference between the higher and lower doses.

Use of etanercept in other conditions

ASTHMA
Thirty-nine patients with severe corticosteroid refractory asthma demonstrated a small but statistically significant improvement in Asthma Control (ACQ) Questionnaire scores after 12 weeks of etanercept, compared to placebo. Larger randomized, placebo controlled trials are required to clarify the role of TNF-α blockers in subjects with severe refractory asthma. [48]

CANCER ANOREXIA/WEIGHT LOSS SYNDROME
Etanercept administered at a dose of 25 mg SC twice-weekly did not appear to palliate the cancer anorexia/weight loss syndrome in 63 patients with advanced disease. [25]

CARDIAC TRANSPLANT RECIPIENTS
Etanercept administered at a dose of 25 mg SC twice weekly did not appear to have a statistically significant effect on the change in left ventricular mass from baseline to 6 months (vs. placebo) in 49 randomized cardiac transplant recipients. [27]

CHRONIC DISCOGENIC LOW BACK PAIN
Etanercept administered as intra-disc injections in an escalating dose protocol did not appear to result in statistically significant improvement in pain or disability scores in 36 patients with low back pain. [28]

EPIDURAL ADMINISTRATION FOR SCIATICA
A small, randomized controlled trial evaluated the effect of the epidural administration of etanercept for the treatment of patients with lumbosacral radiculopathy (sciatica). While suggestive of benefit, larger trials are needed to establish optimal dosage, optimal treatment candidates, and overall safety and efficacy. [52]

GRAFT-VERSUS-HOST DISEASE
No randomized controlled trials have been published evaluating the use of etanercept in patients with graft-versus-host disease.

HEPATITIS C INFECTION
Fifty patients with chronic hepatitis C virus (HCV) infection were randomly assigned to receive interferon alfa-2b and ribavirin with either etanercept or placebo for 24 weeks. At 24 weeks, HCV RNA was absent in 63% (12/19) of etanercept patients compared to 32% (8/25) of placebo patients (P=0.04). The results of this trial are confounded by the small number of patients and the lack of a true ITT analysis. Larger, better designed trials are needed to fully evaluate etanercept for this indication. [26]
METABOLIC SYNDROME

No randomized controlled trials have been published evaluating the use of etanercept in patients with metabolic syndrome using clinically relevant endpoints, such as mortality, progression to development of diabetes, or progression to other diabetic complications.

NON-PLAQUE PSORIASIS

Patients with guttate, erythrodermic, or pustular psoriasis at the time of screening were excluded from the clinical trials and use of etanercept in these conditions is considered investigational. [12]

POLYMYALGIA RHEUMATICA

No randomized controlled trials have been published evaluating the use of etanercept in patients with Polymyalgia Rheumatica.

POLYMYOSITIS

No randomized controlled trials have been published evaluating the use of etanercept in patients with polymyositis.

REACTIVE ARTHRITIS

No randomized controlled trials have been published evaluating the use of etanercept in patients with reactive arthritis.

SARCOIDOSIS

In a small randomized, double-blind, placebo-controlled trial, 18 patients with chronic ocular sarcoidosis were randomized to receive etanercept 25 mg SC twice weekly or placebo for 6 months. There was no apparent reduction in corticosteroid use or improvement in ophthalmology global assessment between the treatment and control groups. [37]

SJÖGREN’S SYNDROME

Twenty-eight subjects with Sjögren’s Syndrome where randomized to receive etanercept 25 mg twice weekly or placebo for 12 weeks in a randomized, controlled fashion. At the end of the study period, there were no significant differences in the subjective measures of disease severity. [24]

TYPE 1 DIABETES

A small, randomized controlled trial was conducted to evaluate the effect of etanercept on A1C in children with newly diagnosed with type 1 diabetes. While suggestive, a larger, trial is needed to establish safety and efficacy. [51]

TYPE 2 DIABETES

No randomized controlled trials have been published evaluating the use of etanercept in patients with type 2 diabetes.
WEGENER’S GRANULOMATOSIS

A randomized, placebo-controlled trial in 180 patients with Wegener’s granulomatosis failed to show a statistically significant improvement in the maintenance of remission in patients treated with etanercept compared to placebo. The trial did reveal statistically significant increases in the risk of solid tumors among patients receiving etanercept. (P=0.01) [38]

Safety of etanercept

Etanercept carries a bolded warning stating that in post-marketing experience, serious infections and sepsis have been reported with the use of etanercept. [1] Additionally, the warning states that rare cases of tuberculosis have been observed in patients treated with TNF-antagonists, including etanercept. The rate of serious infections was found to be higher in patients receiving a combination of etanercept and anakinra (7%) as compared to that in patients receiving either agent alone (0%).[1] Additionally, the combination was not found to result in improved efficacy based on ACR response rates. The safety of etanercept 50 mg twice weekly administered in an open-label fashion for up to 96 weeks in patients with moderate to severe plaque psoriasis was reported. [29]

- The most frequently observed non-infectious events included headache, injection-site hemorrhage, arthralgia, and back pain.
- Rates of infection and serious infections were similar between placebo and etanercept exposures.
- Longer-term studies are needed to detect potential increases in rare events, such as increase incidence of cancer or rare infectious disease.

Longer-term safety data has been published. In general, rates of serious adverse reactions in patients treated up to 7 years in open-label, extension studies was similar to those seen in the shorter-term, randomized controlled trials. Frequent adverse events included upper respiratory infections, flu syndrome, rash and injection-site reactions. [16, 17] A meta-analysis was performed to assess the safety and efficacy of etanercept in elderly subjects with rheumatoid arthritis. A total of 1,353 subjects from 4 randomized controlled clinical trials were included in the analysis. In general, elderly patients tended to have more serious adverse-events than younger patients, but the rate in etanercept-treated elderly patients was similar to placebo-treated and methotrexate-treated elderly patients. [13] Caution should be exercised before considering the use of etanercept in patients with pre-existing or recent onset of central nervous system demyelinating disorders. [1]

Appendix 1: American College of Rheumatology (ACR) Classification Criteria for Establishing the Diagnosis of Rheumatoid Arthritis (RA) [16]

<table>
<thead>
<tr>
<th>Diagnosis of RA requires the presence of at least 4 of 7 criteria below:</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Morning stiffness in and around joints lasting more than 1 hour.</td>
</tr>
<tr>
<td>2. Arthritis in at least 1 area in a wrist or proximal interphalangeal (PIP) joint (hands or fingers) for &gt; 6 weeks.</td>
</tr>
<tr>
<td>3. Simultaneous swelling or fluid accumulation in 3 or more joints for &gt; 6 weeks.</td>
</tr>
<tr>
<td>4. Symmetric (bilateral joint) involvement for &gt; 6 weeks.</td>
</tr>
<tr>
<td>5. Presence of rheumatoid nodules.</td>
</tr>
<tr>
<td>6. Positive serum rheumatoid factor.</td>
</tr>
<tr>
<td>7. Radiographic changes typical of RA (erosion or unequivocal bony decalcification in or adjacent to the involved joint) on hand and wrist present.</td>
</tr>
</tbody>
</table>
Appendix 2: American College of Rheumatology (ACR) Assessment Components for Improvement in Rheumatoid Arthritis (RA) [17]

- Tender joint count.
- Swollen joint count.
- Patient's assessment of pain.
- Patient's global assessment of disease activity.
- Physician's global assessment of disease activity.
- Patient's assessment of physical function.

Appendix 3: Absolute and Relative Contraindications for Phototherapy or Photochemotherapy

Situations where phototherapy may be absolutely or relatively contraindicated include:

- Type 1 or type 2 skin
- History of photosensitivity
- Treatment of facial lesions
- Presence of premalignant lesions
- History of melanoma or squamous-cell carcinoma
- Physical inability to stand for the required exposure time

References


Billing Coding/Physician Documentation Information

| N/A | Enbrel® (etanercept) is a pharmacy benefit. |

Additional Policy Key Words

| N/A |

Related Topics

| N/A |

Policy Implementation/Update Information

| 9/01/2003 | New policy titled Enbrel (etanercept) |
| 9/01/2004 | No policy statement changes. |
| 9/01/2005 | Policy updated to include indication and criteria for psoriasis. |
| 1/01/2006 | Policy statement revised to specify criteria for ankylosing spondylitis manifested as axial disease, peripheral arthritis, or enthesitis. |
| 9/01/2006 | No policy statement changes. |
| 9/01/2007 | No policy statement changes. |
| 9/01/2008 | No policy statement changes. |
| 9/01/2009 | No policy statement changes. |
| 5/01/2010 | Revised policy to reflect BCBSA criteria for RA, AS, Ps, and PsA as defined in policy 5.01.15. |
| 9/01/2010 | No policy statement changes. |
| 9/01/2011 | No policy statement changes. |
| 9/01/2013 | No policy statement changes. |
| 9/01/2014 | No policy statement changes |

This Medical Policy is designed for informational purposes only and is not an authorization, an explanation of benefits, or a contract. Each benefit plan defines which services are covered, which are excluded, and which are subject to dollar caps or other limits. Members and their providers will need to consult the member's benefit plan to determine if there is any exclusion or other benefit limitations
applicable to this service or supply. Medical technology is constantly changing and Blue Cross and Blue Shield of Kansas City reserves the right to review and revise medical policy. This information is proprietary and confidential and cannot be shared without the written permission of Blue Cross and Blue Shield of Kansas City.